Refined Laser Systems
Key Facts
| Invested since | 2022 |
| Based in | North Rhine-Westphalia |
About the company
Refined Laser Systems GmbH, based in Münster, Germany, was founded in 2019 as a spin-off from University of Münster by Max Brinkmann, Tim Hellwig and Christoph Seidenstücker. The company’s core expertise is the development of laser and microscopy technology. The company’s innovative PICUS DUO and PICUS Q laser systems are used worldwide as key components for SRS microscopy and quantum technology. With the long-term goal of making a meaningful contribution to patient well-being and healthcare, Refined Laser Systems is committed to bringing its technology to clinical applications.
Do you want to
know more about this company?
Refined Laser Systems in the news
More startups from Life Sciences
Thermosome is a clinical-stage drug development company focused on targeted tumor therapy combined with immune stimulation for improved cancer therapy. At its core is a novel, proprietary tumor targeting approach …
To the complete profileof Thermosome
miRdetect is a biotechnology company founded in 2016, with the aim to revolutionise cancer diagnostics. The focus is on development, production and distribution of in-vitro diagnostics based on molecular diagnostic …
To the complete profileof miRdetect
TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the …
To the complete profileof TolerogenixX
Exit
Lipocalyx develops transfection reagents. Our Viromers® are polymers emulating a viral mechanism for cell entry. The company provides reagents and currently establishes services for pharmaceutical applications.
To the complete profileof Lipocalyx
Hapila’s counter-current crystallisation process provides a cost effective procedure for purification of active pharmaceutical ingredients, completed by experience in synthesis and particle design.
To the complete profileof HAPILA
oncgnostics develops – based on proprietary epigenetic biomarkers – highly reliable molecular in-vitro diagnostic (IVD) tests for screening, follow-up care and therapeutic decisions in oncology.
To the complete profileof oncgnostics
Exit
KINAXO supports pharmaceutical companies in the development of targeted drugs and predictive biomarkers for personalized healthcare. Exit since Feb. 2011. Purchaser: Evotec AG
To the complete profileof KINAXO
mediaire develops AI-powered diagnostic solutions for MRI imaging, focusing on the seamless integration of AI into clinical workflows to enhance radiologists’ efficiency and diagnostic accuracy. The company’s AI solutions, including …
To the complete profileof mediaire
TRIM TX is developing best-in-class Gamma-Secretase-Stabilizers (GSS) for the prevention and treatment of Alzheimer Disease.
To the complete profileof TRIM TX
Exit
650 million people suffer from mental illness like depression, anxiety or burnout worldwide. Even in developed countries there is a huge treatment gap: 50% do not get treated. Selfapy offers …
To the complete profileof Selfapy
Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system’s power specifically against cancer …
To the complete profileof Abalos
Ebenbuild is a health tech pioneer that creates personalized treatment recommendations for mechanical ventilation and ICU patient care for clinical users. Founded in Munich in 2019, the company develops software …
To the complete profileof Ebenbuild